Stock Research: Champions Oncology

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Champions Oncology

NasdaqCM:CSBR US15870P3073
74
  • Value
    92
  • Growth
    31
  • Safety
    Safety
    18
  • Combined
    42
  • Sentiment
    95
  • 360° View
    360° View
    74
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Champions Oncology, Inc. is a preclinical and clinical research services provider specializing in oncology drug development. The company offers advanced technology solutions and products for personalized oncology drug development. It operates in the biotechnology and pharmaceutical industries. In the last fiscal year, the company had a market cap of $108 million, profits of $21 million, and revenue of $50 million, with 210 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 74 (better than 74% compared with alternatives), overall professional sentiment and financial characteristics for the stock Champions Oncology are above average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Champions Oncology. The consolidated Sentiment Rank has a good rank of 95, which means that professional investors are more optimistic about the stock than for 95% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 92 or better than 92% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 18, meaning that the share price of Champions Oncology is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 31. ...read more

more
Index
Moonshot Tech
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
18 10 42 37
Growth
31 97 25 61
Safety
Safety
92 1 100 100
Sentiment
95 72 18 25
360° View
360° View
74 54 11 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
68 71 3 31
Opinions Change
50 50 95 9
Pro Holdings
n/a 58 1 43
Market Pulse
92 52 55 94
Sentiment
95 72 18 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
18 10 42 37
Growth
31 97 25 61
Safety Safety
92 1 100 100
Combined
42 14 23 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
27 23 1 24
Price vs. Earnings (P/E)
85 64 87 93
Price vs. Book (P/B)
6 1 1 1
Dividend Yield
1 1 1 1
Value
18 10 42 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
61 63 48 43
Profit Growth
9 98 21 98
Capital Growth
13 34 25 29
Stock Returns
79 91 61 43
Growth
31 97 25 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
71 46 100 100
Refinancing
11 6 1 7
Liquidity
98 8 80 80
Safety Safety
92 1 100 100

Similar Stocks

Discover high‑ranked alternatives to Champions Oncology and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.